Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

GLP-1 RAs were associated with positive effects on intracranial hypertension management, including reduced symptoms and treatment burden.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...